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Introduction
Hand-held dynamometry has been used to assess the 
muscle strength of people with neurological disorders 
[2, 13, 17, 33–35]; use has not however been reported in 
people with Huntington’s disease (HD). Huntington’s 
disease is a progressive, neurodegenerative disease that 
results in symptoms of movement disorder. Although 
clinical muscle weakness is not a prominent feature in 
the pre-symptomatic or early symptomatic stages of the 
disorder on routine testing, sub-clinical involvement 
with myopathic change on biopsy [3] and biochemical 
evidence of mitochondrial dysfunction of skeletal mus-
cle has been reported [22]. Given the known evidence of 
early muscle mitochondrial dysfunction (e.g. delayed 
phosphocreatine recovery following aerobic or isch-
aemic exercise even in presymptomatic individuals) 
[24], it was of interest to systematically examine muscle 
strength in the disorder. Weakness, if found, might be 
either due to a disorder of the control of neural excita-
tion processes due to CNS or peripheral nerve disorder 
or due to disordered muscle excitation, activation or en-
ergy exchange processes within muscle or due to re-
duced muscle mass (or a combination of these).
Lower limb muscle weakness may limit functional 
abilities in people with Huntington’s disease (HD). In 
addition significant reductions of muscle strength may 
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■ Abstract  Purpose Sub-clinical 
muscle involvement, including 
 myopathic changes and mitochon-
drial dysfunction of skeletal mus-
cle, has been reported in people 
with Huntington’s disease (HD). 
Muscle strength was evaluated 
 using a hand-held dynamometer. 
Reliability and validity in people 
with HD were determined. Method 
Isometric muscle strength of 6 
lower limb muscle groups was 
measured in 20 people with HD 
and matched healthy controls. 
 People with HD were evaluated 
with the Unified Huntington’s 
 Disease Rating Scales (UHDRS). 
Within session reliability using 
 intra-class correlation coefficients 
(ICC) was calculated. Discriminant 
and convergent validity was also 
evaluated. Results UHDRS motor 
scores of people with HD ranged 
from 28 to 80. Reliability of 
strength testing was excellent (ICC 
0.86 to 0.98). People with HD had 
on average about half the strength 
of healthy matched controls. 
 UHDRS motor scores and strength 
scores were significantly correlated 
(convergent) providing a further 
indication of validity of strength 
testing. Conclusions The hand-held 
dynamometer is a reliable and 
valid measurement tool to detect 
strength differences between peo-
ple with HD and a matched control 
group. There is significant reduc-
tion in lower limb muscle strength 
in HD which does not appear to 
have been described previously. 
■ Key words  muscle strength · 
muscle weakness · Huntington‘s 
Disease · dynamometry · reliability
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occur below the manual testing threshold for weakness 
even in individuals who can maintain routine activities 
of daily living. The incidence of muscle weakness in this 
group needs to be established with the use of objective 
reliable and valid measurements and comparison with 
appropriate control subjects. 
Reliability refers to whether or not a measure can be 
repeated accurately by different assessors (inter-rater) 
and by a single rater (intra-rater) [4]. Documentation of 
any change of muscle strength as a result of an interven-
tion i.e. before and after treatment should incorporate 
knowledge of reliability and take associated variability 
into account. Any measured difference will include some 
variability that could be due to the natural variance of 
the participant or the measuring process or both. 
Reliability is established for the use of hand held dy-
namometers in people with neurological disorders pro-
vided that a specific protocol and trained raters are used 
to perform the testing [8, 34]; however this requires con-
firmation in people with HD. 
Knowledge of the reliability and associated variability 
of tests of muscle strength is important to be able to 
judge whether true changes or differences between pop-
ulations exist whilst knowledge of validity is required to 
make inferences regarding the clinical implications of 
any particular test. Discriminant and convergent validity 
are both considered subcategories of construct validity. 
Tests that are required to detect differences on the same 
construct should discriminate in known groups; this is 
often called known group method [10]. For example peo-
ple with HD may be expected to demonstrate differences 
in muscle strength relative to a healthy matched control 
group as they are known to be clinically different. 
The best known and best validated clinical assess-
ment tool for HD is the Unified Huntington’s Disease 
Rating Scale (UHDRS) [20]. The UHDRS comprises a 
series of semi-quantitative clinical scales to assess mo-
tor function, cognitive function, behavioural abnormal-
ities, and functional capacity. Tests that measure similar 
constructs should converge, for example one might ex-
pect higher UHDRS motor scores in the presence of 
muscle weakness as they indicate greater impairment 
for the motor assessment (UHDRS motor maximum 
possible score (worst) = 124). The UHDRS functional 
scale comprises three components (Functional Assess-
ment Scale (FAS) (minimum possible score (worst) = 0), 
the Independence Scale (IS) (lowest possible score 
(worst) = 5), and the Total Functional Capacity (TFC) 
(lowest possible score (worst) = 0)). It is feasible that 
lower functional scores would be expected in the pres-
ence of muscle weakness [15, 27]. Knowledge of rela-
tions between routinely used current clinical measures 
such as the UHDRS scores can be useful in understand-
ing disease progression and the relative information re-
lating to function that can be gained by utilising strength 
testing in the specific population. 
The aim of this study was to evaluate lower limb 
strength in people with HD using hand-held dynamom-
etry and to assess reliability, related variability and the 
construct validity (represented by any relationships with 
standard clinical measures in HD).
Method
■ Subjects
A convenience sample of 20 symptomatic people with HD and 20 
healthy control subjects were recruited to this study. Inclusion criteria 
for the people with HD were that they had a confirmed diagnosis of 
HD and were able to provide informed consent. They were required 
to be able to walk a distance of 10 metres with or without assistance. 
Inclusion criteria for the healthy subjects were that they had no pe-
ripheral injury or other condition that could impact on muscle 
strength testing. Ethical approval for the study was obtained from the 
local research ethics committee. All subjects provided informed con-
sent before participation. All recruited subjects participated in all 
aspects of the study. 
■ Data collection
Demographic data of age (years), height (cm) and weight (kg) were 
obtained. Scores on the motor section of the Unified Huntington’s 
disease Rating Scale (UHDRS motor), the Total Functional Capacity 
(TFC), the Functional Assessment Scale (FAS) and the Independence 
Scale (IS) were recorded for the people with HD. 
■ Strength testing
The Powertrak hand-held dynamometer (JTech Medical, Utah, USA) 
was used to evaluate muscle strength in this study. Muscle strength 
was defined “as the maximal voluntary force that the subjects were 
able to exert on the environment under the specific testing condi-
tions” [7]. Each subject performed three maximum voluntary isomet-
ric instantaneous contractions for each requested test movement. 
Subjects were instructed to build the force up over 2 seconds and then 
hold that maximum for another 3 seconds. All test movements and 
positions were standardised using a pragmatic approach that mini-
mised the required alteration of body positions for testing whilst al-
lowing the use of simple instructions (Table 1). The right side was 
tested before the left side systematically. Two assessors experienced in 
the use of hand-held dynamometry conducted all the assessments; 
inter-rater reliability was established prior to the start of the study.
 A strength index for each of the three repetitions per muscle 
group and thereafter the best score [16] for each muscle group was 
used to calculate a maximal strength index [36]. The method com-
bines the contribution from all muscle groups into a single index. 
Using the healthy control subject data (n = 20) the strongest muscle 
group, knee extension, was allocated a factor of 1. The factors for all 
the other muscles were calculated as the ratio of average knee exten-
sor strength to the average strength of the muscle tested [36]. Scores 
for each muscle group were then multiplied by the relevant factor and 
summed to produce the final strength index for the right and left 
sides separately. Factors for knee extension, hip extension, hip abduc-
tion, knee flexion, ankle dorsi flexion and ankle plantar flexion were 
1, 1.26, 1.43, 1.55, 1.31 and 1.81 respectively. 
 In order to represent muscle weakness in terms of standard de-
viation units relative to the mean of a healthy matched control group 
[1], a standardised score (z-score) for each variable for the HD group 
was calculated as the difference between the HD group score and the 
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control group average divided by the standard deviation of the con-
trol group. 
■ Data analysis
The Statistical Package for the Social Sciences (SPSS) Version 12 (SPSS 
Inc., Chicago, USA) was used for all data analyses. Within session reli-
ability of the three maximal voluntary contraction attempts in both 
groups (for each muscle group and each side) was assessed with a 
two-way mixed model intra class correlation coefficient (ICC) with 
measures of consistency (ICC 3, 1) [26]. Single measures and average 
measures ICC values [26] were calculated to determine whether one 
repetition (i.e. the best of three attempts [16]) or the average of three 
repetitions was required for reliable testing. As ICC scores are suscep-
tible to sample heterogeneity, the average coefficient of variation 
(CoV), calculated as the standard deviation of the measures expressed 
as a percentage (%) of the mean for the three repetitions [5] was cal-
culated to provide an estimate of any associated error and to allow for 
assessment of differences in variability between groups. Difference 
data were assessed for normality using Q-Q plots and histograms. 
Differences between groups were assessed using independent t-tests 
for interval data and chi square tests for categorical data or where data 
were not normal the appropriate non-parametric equivalent test was 
utilised. Discriminant validity was assessed using the known-groups 
method [10] where differences between people with HD and healthy 
subjects were assessed for each of the calculated variables. 
 Convergent validity of muscle strength testing was assessed by 
examining the correlations (spearman’s correlation coefficients) be-
tween UHDRS scores and a) best of the three maximal strength at-
tempts for individual lower limb muscle groups (right and left) and 
b) a strength index (SI) calculated for each limb [36]. 
■ Sample sizes
The sample sizes were considered sufficient to both characterise reli-
ability and allow for more in-depth between and within group com-
parisons. Twenty subjects tested three times will provide a power of 
80 % (alpha 0.05) [11] where reliability is moderate i.e. 0.6 [26] as 
measured by an intra-class correlation coefficient (ICC). When as-
sessing for differences, 20 subjects per group is sufficient to detect a 
standardised difference of 0.9 [12] and 20 subjects is also sufficient to 
detect a correlation of 0.6 with a power of 80 % and alpha of 0.05 (two-
tailed). 
Results 
■ Subject characteristics
All subjects participated in all parts of the study. The 
mean (SD) age (years), height (cm) and weight (kg) of 
people with HD (n = 20; male = 13) was 51.7 (7.6) years, 
170.8 (9.1) cm and 75.8 (14.1) kg and of healthy controls 
(n = 20; male = 12) was 48.9 (7.3) years, 173.3 (10.5) cm 
and 79.3 (17.9) kg. There were no significant differences 
between groups for any of the matched variables of age, 
height, weight and gender. 
Median (range) UHDRS, TFC, FAS and Independence 
scores were 48 (28–80), 6 (3–11), 17 (7–25) and 72.5 (50–
95) respectively.
■ Strength scores
Reliability using single measures ICC for all the muscle 
groups for each side was excellent and ranged from 0.86 
to 0.96 in both groups; 95 % confidence intervals (CI) 
were in similar ranges. Mean variability was mostly sim-
ilar between groups and ranged from 9.1 % to 15.6 % in 
the HD group and from 5.4 % to 13.9 % in the healthy 
control group. Significantly greater variability relative to 
a healthy control group was identified for ankle dorsi-
flexion muscles. The leg strength index had the highest 
and most precise single measures reliability as well as 
the lowest variability, thus justifying further use of the 
single maximal score of best of three attempts to pro-
duce an MVC and strength index in this population [16]. 
The reliability indices (single and average measures) as 
well as 95 % confidence intervals for the ICC scores and 
measures of variability for each strength score and the 
overall strength index for each limb for healthy control 
subjects and HD group are presented in Table 2. 
People with HD were significantly weaker for all mus-
Table 1  Standardised testing positions for lower limb muscle groups
Muscle action Load cell position Starting position
Hip extension 10 cm proximal to knee joint, in line with the middle of the knee joint Standing facing the plinth, both lower limbs in neutral extension 
(plinth can be used for stabilisation when balancing on single leg)Hip abduction In line with the knee joint, mid-lateral aspect of joint
Knee extension Immediately superior to lateral malleolus of the ankle, anterior 
surface in line with the middle of ankle joint
Sitting on plinth: hips and knees flexed to 90°, hands resting in lap
Knee flexion Immediately superior to lateral malleolus of the ankle, posterior 
surface in line with the middle of ankle joint
Ankle dorsiflexion On the dorsum of the foot in line with second metatarsal of the foot Sitting: hip flexed and knee flexed to 90°, ankle in neutral. Hands 
resting in lap
Ankle plantar flexion On the plantar surface of the foot in line with second metatarsal of 
the foot
Sitting: hips and knees flexed to 90° and ankle in neutral. Hands 
resting in lap
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cle groups and for both sides (right and left) relative to 
the matched healthy control group. The maximal strength 
scores for the individual lower limb muscle groups (right 
and left), and maximal strength indices (SI) as well as 
Z-scores for each limb for the HD group are presented in 
Table 3. On average the strength for the HD group was 
1.55 standard deviations (SD) lower than what was seen 
in the matched healthy control group for the individual 
muscle groups and 1.8 SD less than controls for the SI. 
Correlations between strength and functional scores 
for the HD group only are presented in Table 4. Hip ex-
tension and abduction as well as ankle plantar flexion 
muscle strength were moderately correlated with UH-
DRS scores. Significant correlations with function were 
also identified for the strength indices. 
Discussion
The findings presented indicate that the hand-held dy-
namometer can be considered a reliable measurement 
tool, reflects change in functional abilities in people with 
Table 2  Reliability as measured by intraclass correlation coefficients (ICC) and average coefficients of variation (CoV). Differences between groups for muscles variability 
is also indicated (* p < 0.05)
Muscle action Side HD group (n = 20) Healthy control group (n = 20)
Single measures
ICC 
(95 % CI) 
Average measures
ICC 
(95 % CI) 
Mean (SD) 
CoV % 
Single measures
ICC 
(95 % CI)
Average measures 
ICC 
(95 % CI) 
Mean (SD) 
CoV %
Hip extension Right 0.96 (0.91–0.98) 0.99 (0.97– 0.99) 13.2 (7.0) 0.912 (0.83–0.96) 0.97 (0.94–0.99)  9.4 (4.9)
Left 0.98 (0.95–0.99) 0.99 (0.98– 0.99)  9.1 (5.2) 0.93 (0.86– 0.97) 0.98 (0.95–0.99)  8.9 (3.9)
Hip abduction Right 0.97 (0.93–0.99) 0.99 (0.98– 0.99) 10.1 (5.5) 0.87 (0.75–0.94) 0.95 (0.90–0.98) 12.5 (6.5)
Left 0.97 (0.93–0.99) 0.99 (0.98– 0.99) 10.5 (7.2) 0.92 (0.84–0.97) 0.97 (0.94– 0.99) 12.4 (6.4)
Knee extension Right 0.86 (0.73–0.94) 0.95 (0.89–0.98) 13.6 (17.2) 0.90 (0.80–0.95) 0.96 (0.92–0.98)  8.9 (6.0)
Left 0.89 (0.77–0.95) 0.96 (0.91–0.98) 10.4 (8.2) 0.93 (0.87–0.97) 0.98 (0.95–0.99)  8.1 (5.2)
Knee flexion Right 0.87 (0.75–0.95) 0.95 (0.90–0.98) 13.8 (11.7) 0.93 (0.85–0.97) 0.97 (0.95– 0.99)  9.7 (5.8)
Left 0.88 (0.76–0.94) 0.96 (0.90–0.98) 15.6 (20.1) 0.86 (0.74–0.94) 0.95 (0.89– 0.98) 13.0 (8.7)
Ankle dorsiflexion Right 0.88 (0.77–0.95) 0.96 (0.91–0.98) 15.1 (13.7)* 0.92 (0.84–0.97) 0.97 (0.94– 0.99)  6.9 (4.8)
Left 0.94 (0.88–0.97) 0.98 (0.96–0.99) 11.9 (13.9)* 0.96 (0.92–0.98) 0.99 (0.97– 0.99)  5.4 (3.3)
Ankle plantarflexion Right 0.95 (0.90–0.98) 0.98 (0.97–0.99) 14.1 (11.2) 0.91 (0.82–0.96) 0.97 (0.93– 0.99) 11.0 (5.6)
Left 0.96 (0.92–0.98) 0.99 (0.97–0.99) 10.5 (7.9) 0.89 (0.78–0.95) 0.96 (0.91– 0.98) 13.9 (7.0)
Leg strength Right 0.98 (0.96–0.99) 0.99 (0.98–0.99)  7.5 (4.9) 0.96 (0.92–0.98) 0.99 (0.97– 0.99)  4.7 (2.1)
Left 0.98 (0.96–0.99) 0.99 (0.98–0.99)  6.1 (6.9) 0.97 (0.95–0.99) 0.99 (0.98– 0.99)  5.6 (3.0)
Muscle action Side HD group Healthy control group HD compared to control group
Mean (SD) maximal strength scores (N) Z-scores for
HD group 
95 % CI of difference
for strength scores
Hip extension Right  56.3 (48.3)**  134.6 (49.5) –1.58  46.9–109.6 
Left  52.5 (42.8)**  141.0 (46.8) –1.9  59.78–117.2
Hip abduction Right  56.2 (44.3)**  124.5 (33.8) –2.0  43.1–93.5
Left  52.2 (40.6)**  121.8 (38.4) –1.8  44.3–94.8
Knee extension Right  96.2 (32.1)**  181.7 (65.3) –1.3  52.2–118.9
Left  95.5 (27.1)**  166.5 (61.9) –1.2  39.9–102.1
Knee flexion Right  77.3 (34.4)**  120.9 (39.6) –1.1  19.8–67.3
Left  79.2 (36.9)*  108.8 (39.8) –0.7   5.1–54.2 
Ankle dorsiflexion Right  64.0 (33.5)**  129.7 (35.4) –1.9  43.7–87.8
Left  58.7 (30.2)**  129.4 (33.5) –2.1  50.2–91.1
Ankle plantarflexion Right  43.9 (37.2)**   92.2 (33.2) –1.5  25.7–70.8 
Left  38.7 (32.5)**  107.4 (42.8) –1.6  44.48–93.0 
Leg strength index Right 530.9 (244.5)** 1053.7 (288.6) –1.8 351.5–693.9 
Left 506.1 (227.2)** 1050.9 (293.0) –1.9 376.9–712.6
Table 3  The maximal strength scores 
for the individual lower limb muscle 
groups and strength indices (SI) for 
healthy control group as well as z-scores 
for the HD group and 95 % CI of dif-
ferences between groups. Differences 
(* p < 0.05; ** p < 0.01) between the 
HD group and healthy controls are 
indicated
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HD and is also able to detect strength differences be-
tween people with HD and a matched control group. 
Highest reliability with lower associated variability was 
identified for the leg strength indices. These indices are 
important when considering the relationships of muscle 
strength to function as they allow for the relative contri-
bution of individual muscle groups to a total strength 
score and gives an overall representation of limb strength 
[36].
Significantly greater variability relative to a healthy 
control group was identified for ankle dorsi-flexion 
muscles; this may be a result of the pragmatic testing 
position utilised or the technique of hand-held dyna-
mometry. Testing a larger sample using a fixed dyna-
mometer might help in evaluating this particular find-
ing further. 
The reliability of the hand-held dynamometer has 
been assessed for use in a range of people with neuro-
logical conditions [8, 17, 23, 34] however to our knowl-
edge, not previously in people with HD. The current 
study shows that despite the complex nature of HD, the 
hand-held dynamometer is reliable for use in this popu-
lation. 
People with HD were significantly weaker relative to 
a matched control group. This was reflected both in the 
individual muscle groups as well as by the strength in-
dex and the standardised Z-scores. This gives an indica-
tion of the known-groups validity of hand-held dyna-
mometry. Significant correlations were identified 
between functional scores and strength indices which 
gives a further indication of the validity of such a mea-
sure. 
Muscle strength reduction in HD has been previously 
implied. Mitochondrial dysfunction and morphological 
dysfunction of neuromuscular junctions, potentially 
impacting muscle strength, has been found in HD [3, 
22]. The effects of creatine supplementation in people 
with HD were studied over the period of 1 year [31]. A 5 
–10 % strength reduction over time in people with HD 
was measured for elbow flexors but a healthy control 
group was not studied and therefore it is difficult to say 
whether there were any strength deficits in the first 
place. Grip force variability has also been suggested as a 
measure of disease progression in HD [14, 21]. These 
studies have both focussed only on the upper limb (grip 
force and finger tip forces) and one of these did not in-
clude measurements representing a healthy control 
group [21]. We present data for all the lower limb muscle 
groups tested with a clinically useful measurement de-
vice, including a matched for age, height, weight and 
gender healthy control group. 
This study provides reliable values of muscle strength 
of people with HD compared to age matched healthy 
subjects, but the current study may underestimate the 
muscle strength of the healthy subjects when the data 
obtained is compared to published reference data [6]. 
Specifically the values obtained for the plantar flexors 
are very low considering the weight-bearing function 
and the powerful nature of the muscle group acting over 
a very short lever arm. The plantar flexors were tested in 
a non-weight-bearing gravity eliminated position with 
the knee positioned in flexion. This means that the con-
tribution of the gastrocnemius muscle to the recorded 
output may have been limited and in part may explain 
the low values recorded. There are limited studies exam-
ining ankle plantar-flexors [28] and do not appear to be 
reported in hand-held dynamometry studies [6, 34]. 
This may be due to the technical difficulties experienced 
in standardising testing positions for this muscle 
group. 
Muscle action Side UHDRS
motor 
scores
UHDRS total
functional
capacity 
UHDRS
functional 
assessment scale
UHDRS
independence
scale
Hip extension Right –0.62** 0.69** 0.74**  0.71**
Left –0.70** 0.71** 0.72**  0.69**
Hip abduction Right –0.67** 0.65** 0.69**  0.65**
Left –0.74** 0.66** 0.69**  0.68**
Knee extension Right –0.03 0.03 0.16 –0.06
Left –0.14 0.12 0.21  0.05
Knee flexion Right –0.15 0.41 0.45  0.35
Left –0.14 0.36 0.393  0.295
Ankle dorsiflexion Right –0.06 0.06 0.08 –0.03
Left –0.14 0.20 0.25  0.13
Ankle plantarflexion Right –0.51* 0.59* 0.59*  0.54*
Left –0.49* 0.57* 0.59*  0.58*
Leg strength index Right –0.56** 0.62** 0.64**  0.56*
Left –0.60** 0.61** 0.64**  0.56*
Table 4  Spearman’s correlation coefficients (rs) 
between UHDRS scores and strength scores (HD 
group only). Significant correlations are indicated 
(* p < 0.05; ** p < 0.01)
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Differences from the published literature may be ex-
plained by different testing protocols and devices used. 
There is a potential ceiling effect related to strength test-
ing using hand-held dynamometry and there are fur-
ther limitations due to stable position of the device, dis-
comfort of the subject and the strength of the tester 
applying resistance with the hand-held dynamometer 
[32]. These latter issues could impact upon the data for 
healthy matched control subjects more than that of 
weaker people with HD with the resulting potential to 
underestimate strength differences.
People with HD were significantly weaker than age 
and gender matched control subjects. We suggest that 
decline in muscle strength in people with HD may be as 
a result of multiple components. Alteration of muscle 
tone seen in HD may lead to loss of motor unit activa-
tion, changes in the recruitment ordering and firing rate 
as proposed in stroke [25]. These changes may impair 
ability to produce a maximum voluntary muscle con-
traction effectively and consistently in people with HD, 
hence leading to the suggestion of increased variability 
[21]. This variability has been represented by the coef-
ficient of variation in this study but the data did not con-
firm increased variability of lower limb measurements 
in people with HD relative to healthy controls, thus mak-
ing this sole explanation for weakness unlikely. Whether 
the documented weakness is a primary manifestation of 
a pathological process relating to HD within muscle or 
is secondary to altered motor unit activation processes 
or to muscle wasting consequent on changed patterns of 
mobility or muscle usage is currently unclear.
Muscle weakness may be an important but under-re-
ported clinical feature in HD contributing to disability 
and muscle strengthening interventions could be con-
sidered relevant for this patient group. Improvement of 
muscle strength in people with HD due to muscle 
strengthening interventions have been documented in 
small scale uncontrolled studies [18] although focus is 
usually on balance and postural impairments [19]. Loss 
of muscle strength in parallel with the other symptoms 
of the disease may contribute to physical inactivity. Lack 
of physical activity as a potential factor in muscle weak-
ness has been discounted as a factor in the previous 
study of mitochondrial dysfunction [24], although in 
this case the researchers did not carry out in-depth 
monitoring of physical activity but relied on self report 
to determine physical status. Long-term community-
based activity monitoring [9] should be used to provide 
evidence of associated levels of physical activity. There 
is evidence of a relationship between decreased activity 
and worsening symptoms especially voluntary move-
ments as measured by wrist-worn activity monitors 
[30]. 
Physical inactivity in parallel with the aforemen-
tioned issues may further induce plastic changes to 
muscles such as substantial atrophy in muscles that play 
an anti-gravity role, fiber-type transformations and 
myofibril protein loss [29]. In this situation, strength 
loss would be generalized to all the inactive muscles. In 
this study, the loss of muscle strength was not restricted 
to selected muscle groups of the lower limbs; the pattern 
of weakness was non-specific. This lends support to 
physical inactivity as being one of a range of potential 
mechanisms of the reported weakness. Further in-depth 
investigations using robust strength testing measures 
and neurophysiological techniques including twitch in-
terpolation to test muscle activation processes alongside 
molecular investigations may help elucidate the cause of 
weakness.
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